Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms
Cancer Medicine · 2024
DOI: 10.1002/cam4.7093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Kelly S Chien und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Neoplasms, Myeloproliferative Disorders. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, University of Texas MD Anderson Cancer Center.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The occurrence of somatic mutations in patients with no evidence of hematological disorders is called clonal hematopoiesis (CH). CH, whose subtypes include CH of indeterminate potential and clonal cytopenia of undetermined significance, has been associated with both hematologic cancers and systemic comorbidities. However, CH's effect on patients, especially those with concomitant malignancies, is not fully understood.
Methods
We performed a retrospective evaluation of all patients with CH at a tertiary cancer center. Patient characteristics, mutational data, and outcomes were collected and analyzed.
Results
Of 78 individuals included, 59 (76%) had a history of cancer and 60 (77%) had moderate to severe comorbidity burdens. DNMT3A , TET2 , TP53 , and ASXL1 were the most common mutations. For the entire cohort, the 2‐year overall survival rate was 79% (95% CI: 70, 90), while the median survival was not reached. Of 20 observed deaths, most were related to primary malignancies ( n = 7, 35%), comorbidities ( n = 4, 20%), or myeloid neoplasms ( n = 4, 20%). Twelve patients (15%) experienced transformation to a myeloid neoplasm. According to the clonal hematopoiesis risk score, the 3‐year transformation rate was 0% in low‐risk, 15% in intermediate‐risk ( p = 0.098), and 28% in high‐risk ( p = 0.05) patients. By multivariate analysis, transformation was associated with variant allele frequency ≥0.2 and hemoglobin
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Kelly S Chien, Kunhwa Kim, Rashmi Kanagal-Shamanna, Courtney D DiNardo, Guillermo Montalban-Bravo, Hagop M Kantarjian
Förderung
- NCI NIH HHS
- University of Texas MD Anderson Cancer Center
Zitieren
APA
Chien, K. S., Ong, F., Kim, K., Li, Z., Kanagal-Shamanna, R., DiNardo, C. D., Takahashi, K., Montalban-Bravo, G., Hammond, D., Sasaki, K., Pierce, S. A., Kantarjian, H. M., & Garcia-Manero, G. (2024). Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms. Cancer Medicine. https://doi.org/10.1002/cam4.7093
Vancouver
Chien KS, Ong F, Kim K, Li Z, Kanagal-Shamanna R, DiNardo CD, et al. Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms. Cancer Medicine. 2024. doi:10.1002/cam4.7093
BibTeX
@article{Chien2024,
author = {Chien, Kelly S and Ong, Faustine and Kim, Kunhwa and Li, Ziyi and Kanagal-Shamanna, Rashmi and DiNardo, Courtney D and Takahashi, Koichi and Montalban-Bravo, Guillermo and Hammond, Danielle and Sasaki, Koji and Pierce, Sherry A and Kantarjian, Hagop M and Garcia-Manero, Guillermo},
title = {Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7093}
}
EUVIMED